Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-EB-TATE in Advanced Neuroendocrine Tumors
NCT05475210Phase 1Completed
- Sponsor
- Molecular Targeting Technologies, Inc.
- Start
- Jun 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EBTATE in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Molecular Targeting Technologies, Inc. Primary endpoints: Number of patients with treatment-related adverse events, Dose-limiting toxicities and 1 more. Started Jun 2022; status: completed.
02
Drugs
EBTATE
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05475210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475210.